Head-to-head evidence
Apomorphine sublingual film (Kynmobi) vs LY03003
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine · full Parkinson's Disease pipeline
Apomorphine sublingual film (Kynmobi)
Marketed by Sumitomo Pharma
NCT02469090 · Phase 3 · completed
The study randomized 109 patients to apomorphine sublingual film or matching placebo in a quadruple-blind design, with 54 patients receiving apomorphine and 55 receiving placebo. The primary clinical motor-function endpoint was met: the MDS-UPDRS Part III score improved more with apomorphine than placebo at Week 12 (p=0.0002).
LY03003
Developed by Luye Pharma Group
NCT04571164 · Phase 3 · completed
The trial randomized 294 participants to LY03003 or placebo and masked participants, care providers, investigators, and outcome assessors. Its primary endpoint was change in the clinical UPDRS parts II+III score over 24 weeks, but the primary comparison and safety findings are not available, preventing assessment of whether the endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Apomorphine sublingual film (Kynmobi)'s landscape · LY03003's landscape